- Home
- GGR vs IPHA Comparison
GGR vs IPHA Comparison
Compare GGR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGR
- IPHA
- Stock Information
- Founded
- GGR 2011
- IPHA 1999
- Country
- GGR Taiwan
- IPHA France
- Employees
- GGR N/A
- IPHA N/A
- Industry
- GGR Auto Manufacturing
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- GGR Consumer Discretionary
- IPHA Health Care
- Exchange
- GGR Nasdaq
- IPHA Nasdaq
- Market Cap
- GGR 166.7M
- IPHA 160.1M
- IPO Year
- GGR N/A
- IPHA 2019
- Fundamental
- Price
- GGR $0.45
- IPHA $2.24
- Analyst Decision
- GGR Hold
- IPHA Strong Buy
- Analyst Count
- GGR 2
- IPHA 1
- Target Price
- GGR $0.50
- IPHA $11.50
- AVG Volume (30 Days)
- GGR 508.9K
- IPHA 650.0K
- Earning Date
- GGR 02-13-2025
- IPHA 03-20-2025
- Dividend Yield
- GGR N/A
- IPHA N/A
- EPS Growth
- GGR N/A
- IPHA N/A
- EPS
- GGR N/A
- IPHA N/A
- Revenue
- GGR $329,041,000.00
- IPHA $36,202,722.00
- Revenue This Year
- GGR N/A
- IPHA N/A
- Revenue Next Year
- GGR $3.73
- IPHA $93.37
- P/E Ratio
- GGR N/A
- IPHA N/A
- Revenue Growth
- GGR N/A
- IPHA N/A
- 52 Week Low
- GGR $0.40
- IPHA $1.29
- 52 Week High
- GGR $2.02
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- GGR 47.08
- IPHA 63.01
- Support Level
- GGR $0.44
- IPHA $2.07
- Resistance Level
- GGR $0.50
- IPHA $2.38
- Average True Range (ATR)
- GGR 0.03
- IPHA 0.13
- MACD
- GGR 0.00
- IPHA 0.04
- Stochastic Oscillator
- GGR 46.45
- IPHA 78.79
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.